Clinical Trials Directory

Trials / Completed

CompletedNCT01318148

Pharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal Prophylaxis

Prospective Trial to Evaluate Pharmacokinetic, Safety and Efficacy of Intermittent Application of Increased Doses of Caspofungin for Antifungal Prophylaxis in High Risk Patients

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
25 (actual)
Sponsor
Werner J. Heinz · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study is a pilot phase II, prospective, non-comparative, single center trial aimed to evaluate pharmacokinetic and safety of an intermittent dosing schedule for antifungal prophylaxis in high risk patients.

Detailed description

Pharmacokinetic and safety of caspofungin, in an intermittent dosing schedule, for prophylaxis of invasive fungal (IFI) infections will be evaluated in patients receiving induction chemotherapy for treatment of acute myeloid leukemia, myelodysplastic syndrome with blast crisis or acute lymphatic leukemia. For prophylaxis caspofungin once daily will be given three times a week after a loading phase of three days. For drug monitoring serum samples will be collected from the first day of trial medication till one day after end of therapy (EOT). Invasive fungal infections will be diagnosed analog the criteria defined by the European organization for Research and Treatment of Cancer and the Mycosis Study Group (EORTC/MSG), revised in 2008. Caspofungin prophylaxis will be stopped after the end of neutropenia, in case of documented proven or probable invasive fungal disease and in case of a serious adverse event attributable to the study drug, for which in view of the investigator further usage of the study drug should be avoided.

Conditions

Interventions

TypeNameDescription
DRUGcaspofunginIntermittent intravenous application of caspofungin

Timeline

Start date
2011-04-01
Primary completion
2013-09-01
Completion
2013-10-01
First posted
2011-03-18
Last updated
2014-01-09

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT01318148. Inclusion in this directory is not an endorsement.